KRAS Activating Mutation clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
at UCSF
Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Sorry, in progress, not accepting new patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
at UCSF
Our lead scientists for KRAS Activating Mutation research studies include Andrew Ko.
Last updated: